Turning REST/NRSF Dysfunction in Huntington's Disease into a Pharmaceutical Target

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|15|34|3958-3967

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.15, Iss.34, 2009-12, pp. : 3958-3967

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ABAD: A Potential Therapeutic Target for A&bgr;-Induced Mitochondrial Dysfunction in Alzheimer's Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 8, 2009-07 ,pp. : 1002-1008

Bentham Science Publishers

Access to resources Recommend Favorite

Mouse models of Huntington's disease

By Menalled L.B.   Chesselet M.-F.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 1, 2002-01 ,pp. : 32-39

Elsevier

Access to resources Recommend Favorite

The Endocannabinoid System and Huntington's Disease

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 5, 2003-10 ,pp. : 335-347

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotection in Huntington;s Disease

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 2, 2005-03 ,pp. : 143-147

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: VDAC As a Pharmaceutical Target

By  

Current Medicinal Chemistry, Vol. 24, Iss. 40, 2018-01 ,pp. : 4417-4418

Bentham Science Publishers

Access to resources Recommend Favorite